Research Paper Volume 13, Issue 4 pp 5358—5368
The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE
Figure 2. Subgroup analyses of overall survival for HCC patients who underwent TACE according to various tumor characteristics. (A) Age≤60 years; (B) age>60 years; (C) HBV positive; (D) absence of viral hepatitis (E) AFP≤200 ng/ml, (F) AFP>200 ng/ml, (G) ALBI grade 1, (H) ALBI grade 2, (I) greatest tumor size≤5 cm, (J) greatest tumor size>5 cm, (K) absence of macroscopic vascular invasion; (L) presence of macroscopic vascular invasion, (M) absence of extrahepatic metastasis; (N) presence of extrahepatic metastasis; (O) BCLC stage A, (P) BCLC stage B, (Q) BCLC stage C.